

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> GlaxoSmithKline UK (mepolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Allergy UK Asthma Relief Charity Asthma UK Fifth Sense NARA – The Breathing Charity South Asian Health Foundation Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Anaesthetists Association of Respiratory Nurse Specialists Association of Surgeons of Great Britain and Ireland British Rhinological Society British Society for Allergy and Clinical Immunology British Association of Otolaryngologists, Head & Neck Surgeons British Geriatrics Society ENT UK Primary Care Respiratory Society UK Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> ADVANZ Pharma (prednisolone) Accord (prednisolone) Allergan (prednisolone) Alliance Pharmaceuticals (prednisolone) Almus Pharmaceuticals (prednisolone, mometasone furoate) Cipla EU Ltd (mometasone furoate) Genesis Pharmaceuticals (prednisolone) GlaxoSmithKline (fluticasone furoate) Merck Sharp & Dohme (mometasone furoate)

Provisional stakeholder list for the technology appraisal of mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps ID3817

Issue date: September 2020

© National Institute for Health and Care Excellence 2020. All rights reserved

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Lincolnshire East CCG • NHS South Warwickshire CCG • Welsh Government 	<ul style="list-style-type: none"> • Phoenix Labs (prednisolone) • Sandoz (mometasone furoate) • Strides Pharma UK (prednisolone) • Teva (prednisolone) • Wockhardt UK (prednisolone) • Zentiva (prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Asthma, Allergy and Inflammation Research Trust • Cochrane Airways Group • Cochrane Ear, Nose and Throat Disorders Group • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.